PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
This memorandum is protected by the attorney-client privilege and the work-product doctrine. It is prepared in anticipation of litigation and should not be disclosed to any person outside Calderwood & Harkness LLP and authorized representatives of Meridian Consumer Brands LLC without prior written consent.
INTERNAL MEMORANDUM
Calderwood & Harkness LLP 600 Lexington Avenue, 30th Floor New York, New York 10022
Matter Number: 1011-00004
Date: September 12, 2025
To: Linda Osei, Responsible Partner, Litigation (General)
From: Patrick Gallagher, Lead Associate, Litigation (General) Simone Laroche, Working Associate, Litigation (General)
Re: Pre-Suit Investigation — Analysis of False Advertising Claims by Apex Naturals Inc. Against Meridian Consumer Brands LLC's DermaTrūe Product Line; "The PuraClear Truth" Campaign
I. Executive Summary
Calderwood & Harkness LLP has been retained by Meridian Consumer Brands LLC ("Meridian" or "MCB") — a Delaware limited liability company with its principal place of business in New York, New York — to evaluate potential claims against Apex Naturals Inc. ("Apex" or "ANI"), a Delaware corporation headquartered in Parsippany, New Jersey. The claims arise from Apex's nationwide comparative advertising campaign branded "The PuraClear Truth" (internally known at Apex as "Project Clarity"), which targets Meridian's flagship DermaTrūe acne-treatment and blemish-treatment product family.
The campaign launched on June 2, 2025, and has been disseminated across an unusually broad array of media channels, including: national television (both 30-second and 60-second spot advertisements), digital and social media platforms (Crowne Albany Partners LLC, Dunmore & Co., and Northpoint Services Inc. Reels), in-store point-of-sale ("POS") displays at major drugstore retail chains nationwide, print advertisements in leading consumer magazines, and a dedicated campaign landing page hosted on the Apex corporate website at www.apexnaturals.com/puraclear-truth. The campaign's scope and multi-channel saturation reflect a substantial financial commitment by Apex. Based on third-party media-spend tracking data and publicly available rate-card information, we estimate the total campaign expenditure from June through August 2025 at approximately $23.0 million, with $14.3 million allocated to television media buys and approximately $8.7 million allocated to digital and social media placements.
Our investigation has identified three principal categories of false or misleading claims made by Apex's campaign about the PuraClear acne-treatment product line relative to Meridian's DermaTrūe product family:
1. The Fabricated Clinical Superiority Claim. The campaign asserts that "In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment," citing a non-existent published study in a non-existent journal. The sole basis for the claim appears to be a deeply flawed internal Apex pilot study with only 22 participants, a non-blinded design, and no control group.
2. The Misleading Price-Per-Unit Comparison. The campaign states that "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit." This claim compares a single 1.0 oz. PuraClear tube ($12.99/oz.) against a three-piece, 5.2 oz. DermaTrūe Complete Acne System ($5.57/oz.), inverting the actual per-ounce price relationship and falsely labeling the products as "comparable."
3. The False "Clean" Ingredients Claim. The campaign declares that "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances." In fact, Meridian reformulated its DermaTrūe line in 2024 under the sub-brand "DermaTrūe Pure," which is independently verified to be free of all three ingredients. This claim was demonstrably false at the time the campaign launched.
This memorandum analyzes each claim category in detail, assesses the available evidence, identifies evidentiary gaps requiring further investigation or discovery, and evaluates the viability of claims under the Lanham Act § 43(a) (15 U.S.C. § 1125(a)), New York General Business Law §§ 349 and 350, common-law unfair competition, and tortious interference with business relations.
Bottom-line conclusion: All three claim categories are strong candidates for litigation. The clinical superiority claim is the strongest and is likely literally false on its face, requiring no extrinsic evidence of consumer deception. The price-comparison claim is, at minimum, implicitly misleading and likely literally false with respect to the use of the word "comparable." The clean-ingredients claim is literally false. Consumer survey evidence developed by Dr. Eleanor Fisk of Fisk Analytics Group LLC reinforces the showing of actual consumer deception across all claim categories. Meridian has sustained significant, quantifiable financial harm — including a $7.4 million quarter-over-quarter revenue decline for DermaTrūe in Q3 2025 and a pending 30% shelf-space reduction at Kingsley Drug Stores LLC — as well as substantial, ongoing brand-perception damage.
We recommend that Meridian proceed with the filing of a verified complaint asserting all five causes of action in the United States District Court for the Southern District of New York, accompanied by an expedited motion for a preliminary injunction, on a target filing date of September 26, 2025.
II. Background
A. The Parties
1. Meridian Consumer Brands LLC
Meridian Consumer Brands LLC is a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001. Meridian develops, manufactures, and markets premium skincare, personal-care, and over-the-counter ("OTC") dermatological products sold through major retail chains, specialty retailers, and direct-to-consumer e-commerce channels nationwide. Meridian's product portfolio includes three principal brand families:
• DermaTrūe — Meridian's flagship line of acne-treatment and blemish-treatment products, including cleansers, spot treatments, treatment gels, moisturizers, and multi-product acne-care systems. The DermaTrūe line was reformulated in 2024 under the "DermaTrūe Pure" sub-brand to eliminate parabens, sulfates, and synthetic fragrances in response to evolving consumer demand for "clean beauty" formulations.
• Velara — A premium anti-aging skincare line.
• SkinSense — A sensitive-skin product line designed for consumers with dermatological sensitivities.
For the fiscal year ended December 31, 2024, Meridian reported total revenue of $487.6 million (as audited by Ashford & Kline LLP, its independent auditor). The DermaTrūe product line accounted for $138.2 million of that total, representing approximately 28.3% of Meridian's consolidated revenue. DermaTrūe is thus the single most significant revenue driver for the company, and any material impairment of its market position and brand equity directly threatens Meridian's financial performance and enterprise value.
Meridian was acquired in 2019 by Brindoval Capital Partners Fund IV LP, a private equity fund, and operates as a portfolio company of the Brindoval Capital Partners platform. Meridian's senior management team includes:
• Nathan Hartwell — Chief Executive Officer
• Julia Whitmore — Chief Marketing Officer
• Derek Cho — General Counsel
• Dr. Annika Patel — Vice President, Regulatory & Scientific Affairs
2. Apex Naturals Inc.
Apex Naturals Inc. is a Delaware corporation with its principal place of business at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex develops, manufactures, and markets mass-market and "clean-beauty" skincare and acne-treatment products sold primarily through drugstore retail channels (including CVS, Walgreens, Adriatic & Co., and Kingsley Drug Stores) and e-commerce platforms. Apex's product portfolio includes three principal brand families:
• PuraClear — Apex's primary acne-treatment product line, which competes directly with Meridian's DermaTrūe family.
• GreenVeil — A line of facial and body moisturizers.
• ClearPath — A body-wash product line.
Based on publicly available financial information and third-party market intelligence data, Apex's total revenue for the fiscal year ended December 31, 2024 is estimated at approximately $312.4 million. The PuraClear product line is estimated to have generated approximately $89.7 million, or 28.7% of Apex's total revenue. PuraClear and DermaTrūe are thus each the flagship brands for their respective companies, and the two brands are the primary direct competitors in the premium acne-treatment category. Apex's senior personnel include:
• Marcus Devlin — Chief Executive Officer & Founder
• Rachel Emory — Chief Marketing Officer
• Dr. Simon Guerrero — Vice President, Product Development
• Tanya Fischetti — General Counsel
Apex is represented by outside litigation counsel at Caldwell, Briggs & Nolan LLP, 200 Park Avenue, 42nd Floor, New York, New York 10166. The lead partner on the matter is Harrison Briggs; Leah Tannenbaum serves as the primary associate. Caldwell, Briggs & Nolan responded to Meridian's cease-and-desist letter on Apex's behalf and has been the point of contact for all pre-litigation communications.
3. Brightline Creative Partners LLC
Brightline Creative Partners LLC is a full-service advertising and creative agency located at 55 Washington Street, Suite 900, Brooklyn, New York 11201. Brightline was retained by Apex to develop and execute "The PuraClear Truth" campaign. Brightline's Chief Creative Officer, Owen Prescott, is believed to have had direct involvement in the conceptualization and creative execution of the campaign's advertising copy, including the three claim categories analyzed in this memorandum. Brightline may be added as a defendant or, alternatively, may be a key source of evidence regarding the development and approval process for the campaign's factual assertions.
B. Pre-Litigation Chronology
The following timeline summarizes the key events preceding and informing this investigation:
C. Overview of Campaign Content
"The PuraClear Truth" campaign is a coordinated, multi-channel comparative advertising initiative targeting Meridian's DermaTrūe product family. The campaign runs across the following platforms:
• National television: 30-second and 60-second spot advertisements airing on broadcast and cable networks during prime-time, daytime, and late-night programming.
• Digital video: Pre-roll, mid-roll, and standalone video advertisements on Crowne Albany Partners LLC, as well as sponsored content on Dunmore & Co. and Northpoint Services Inc. Reels.
• In-store POS displays: Branded counter cards, shelf talkers, and endcap displays placed in drugstore retail locations nationwide, including Kingsley Drug Stores, CVS, and Walgreens locations.
• Print advertisements: Full-page and half-page advertisements in consumer magazines, including Allure, Cosmopolitan, Self, and Women's Health.
• Dedicated landing page: A campaign-specific microsite at www.apexnaturals.com/puraclear-truth featuring aggregated campaign content, product comparison charts, and links to purchase PuraClear products.
The campaign's creative direction employs a direct comparative advertising format. Advertisements prominently feature the DermaTrūe brand name and product imagery alongside PuraClear products, with visual and textual elements designed to position PuraClear as clinically superior, less expensive, and formulated with cleaner ingredients than DermaTrūe. The campaign makes three distinct categories of factual claims, each of which we analyze in detail in the sections that follow.
III. Analysis of Claim Category 1: The Fabricated Clinical Superiority Claim
A. The Claim as Made
The campaign's clinical superiority claim is presented in substantially the following verbatim form across television spots, digital video advertisements, and the campaign landing page:
"In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment."
In the television and digital video versions, the claim is read by a voiceover narrator while the screen displays side-by-side images of a PuraClear product and a DermaTrūe product, accompanied by a graphic chart purporting to show a bar comparison of blemish-reduction rates. Beneath the claim, in small print (approximately 8-point type on screen for less than three seconds), the advertisement cites the following source attribution:
"Guerrero et al., 2024, Independent Dermatological Review."
On the campaign landing page, the same claim is presented in large-format text with the source citation hyperlinked — but the hyperlink leads to a generic Apex product page rather than to any published study or journal.
B. Investigation Findings
Our investigation has revealed that the published study cited in the advertisement does not exist, and that the underlying data upon which the clinical claim appears to be based is derived from a severely flawed internal Apex pilot study that does not support the "47% faster" efficacy assertion.
No published study exists. We conducted extensive searches of peer-reviewed dermatological and medical journals, including searches of PubMed, MEDLINE, the Cochrane Library, Embase, and Severin Industries Scholar. We also searched the databases of the American Academy of Dermatology, the Journal of the American Academy of Dermatology, the British Journal of Dermatology, the Journal of Investigative Dermatology, and all other indexed dermatological publications. These searches reveal no publication titled or authored as "Guerrero et al., 2024" in any journal called the "Independent Dermatological Review." Moreover, no journal by the name "Independent Dermatological Review" appears in any standard indexing database, including PubMed, the National Library of Medicine Catalog, Ulrich's Periodicals Directory, or the Directory of Open Access Journals. In short, the journal cited in the advertisement does not appear to exist, and neither does the study attributed to it.
The underlying data comes from an internal Apex pilot study. Based on publicly available information, Meridian's competitive intelligence, and information obtained through the NAD proceeding, the sole basis for the "47% faster" claim appears to be an internal Apex study conducted under the direction of Dr. Simon Guerrero, Apex's Vice President of Product Development. Our analysis of publicly available information about this study reveals critical methodological deficiencies that render its conclusions scientifically unreliable:
• Grossly inadequate sample size. The study involved only 22 participants. In the field of dermatological efficacy research, the minimum sample size for a statistically meaningful clinical study of acne-treatment products is generally accepted to be no fewer than 100 participants, with many regulatory-grade studies enrolling 200 or more. A 22-person study lacks the statistical power to detect meaningful differences between products and is highly susceptible to random variation and outlier effects. Any reported percentage difference (e.g., "47% faster") derived from such a small sample cannot be considered statistically significant.
• Non-blinded design. The study was not blinded — participants and evaluators were aware of which product was being applied during the trial. Non-blinded designs introduce substantial observer bias (evaluators may rate outcomes more favorably for the product they expect to be superior) and placebo bias (participants' expectations may influence their subjective assessments and even their physiological responses). The absence of blinding is a fundamental methodological deficiency that undermines the reliability of the study's findings.
• No control group. The study did not include a placebo or untreated control arm. Without a control group, there is no basis for attributing any observed improvements in acne blemishes to either product rather than to natural variation, regression to the mean, or other confounding factors unrelated to product efficacy. The absence of a control group renders the study's comparative conclusions inherently unreliable.
Expert evaluation anticipated. We have identified Dr. Miriam Salazar, a board-certified dermatologist and associate professor in the Department of Dermatology at Graystone University Medical Center (550 First Avenue, New York, New York 10016), as a scientific expert qualified to opine on the inadequacy of the Apex pilot study design and the scientific invalidity of the "47% faster" efficacy claim. Dr. Salazar has published extensively on clinical trial methodology in dermatology and has served as an expert witness in prior false-advertising cases involving dermatological product claims. Her engagement rate is $750 per hour.
Deliberate fabrication of scientific credibility. The citation of a non-existent publication in a non-existent journal is not a mere technical error or inadvertent omission. The format of the citation — author name, year, journal title — is specifically designed to mimic the conventions of peer-reviewed scientific publication and to convey to consumers and healthcare professionals that the "47% faster" claim has been validated through independent, peer-reviewed scientific research. This constitutes a deliberate attempt to lend false scientific credibility to a claim that lacks any legitimate scientific basis.
C. Legal Analysis — Literal Falsity
Under the Lanham Act § 43(a), 15 U.S.C. § 1125(a), a plaintiff asserting a false advertising claim must establish that the defendant made a false or misleading statement of fact in commercial advertising or promotion. The Second Circuit has recognized two distinct categories of actionable claims: (1) claims that are literally false on their face, and (2) claims that, while not literally false, are misleading or likely to deceive consumers. See Calderon Corporation Eprova AG v. Gnosis S.p.A., 760 F.3d 247, 255 (2d Cir. 2014); McNeil-PPC, Inc. v. Northpoint Holdings, 351 F. Supp. 2d 226, 248-49 (S.D.N.Y. 2005).
Where a claim is literally false, no extrinsic evidence of consumer confusion or deception is required; the court may grant relief based on the falsity alone. See Calderon Corporation Eprova, 760 F.3d at 256 ("[W]here the advertisement is literally false, a violation may be established without evidence of consumer deception."). This principle substantially simplifies the plaintiff's burden and strengthens the case for preliminary injunctive relief.
The clinical superiority claim is literally false in at least three independent respects:
First, the claim states that PuraClear was tested "in a controlled clinical study." The underlying Apex pilot study was not a controlled study — it had no control group, was not blinded, and lacked the basic methodological features of a controlled clinical trial. The description of the study as "controlled" is literally false.
Second, the advertisement cites "Guerrero et al., 2024, Independent Dermatological Review" as the source for the claim. This publication does not exist, and the journal in which it is purportedly published does not exist. The citation is literally false.
Third, the "47% faster" efficacy figure lacks any valid scientific substantiation. The figure is derived from a study that is statistically insignificant, methodologically flawed, and incapable of supporting the comparative efficacy conclusion the advertisement attributes to it. To the extent the advertisement asserts that the "47% faster" claim is a scientifically established fact, that assertion is literally false.
Strength of claim: Very strong. This is the most straightforward and compelling of the three claim categories. The fabrication of a study citation and the gross inadequacy of the underlying data likely establish both literal falsity and willfulness — the latter being relevant to the availability of enhanced damages, attorneys' fees, and the weight of the equitable factors on a preliminary injunction motion. The deliberate creation of a fictitious journal citation, in particular, is the type of conduct courts have found to warrant enhanced remedies. See, e.g., Calderon Corporation Eprova, 760 F.3d at 264-65 (affirming award of profits and attorneys' fees where false advertising was willful); Church & Dwight Co. v. SPD Swiss Precision Diagnostics, GmBH, 843 F.3d 48, 66 (2d Cir. 2016) (discussing willfulness standard).
D. Evidentiary Gaps and Further Investigation Needed
While the evidence currently available is sufficient to support the filing of a complaint and a preliminary injunction motion, the following evidentiary gaps should be addressed through discovery or pre-litigation demands:
1. Full details of the Apex internal pilot study. We need to obtain the complete study protocol, raw data, statistical analyses, participant enrollment records, informed consent forms, and any interim or final study reports. These materials will allow our scientific expert, Dr. Salazar, to prepare a comprehensive opinion on the study's methodological deficiencies and the invalidity of the "47% faster" claim.
2. Internal communications regarding the clinical claim. Communications between Dr. Simon Guerrero, Rachel Emory (CMO), Marcus Devlin (CEO), and Brightline Creative Partners LLC (Owen Prescott) regarding the formulation, vetting, and approval of the clinical superiority claim are likely to reveal whether Apex personnel and their advertising agency were aware of the limitations of the pilot study and made a deliberate decision to present it as a peer-reviewed, controlled clinical trial.
3. Knowledge of the fabricated citation. Any internal communications acknowledging that the "Independent Dermatological Review" journal does not exist, or discussing the decision to create a citation formatted to appear as a peer-reviewed publication, would be particularly powerful evidence of willfulness and intent to deceive.
4. Expert report. A formal expert report from Dr. Miriam Salazar is needed to establish the scientific standard for dermatological efficacy studies, to analyze the specific deficiencies of the Apex pilot study, and to opine that the study cannot support the "47% faster" claim.
IV. Analysis of Claim Category 2: The Misleading Price Comparison
A. The Claim as Made
The campaign's price-comparison claim is presented in substantially the following verbatim form across television spots, in-store POS displays, and print advertisements:
"PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit."
In the television advertisements, this claim is displayed as an on-screen graphic showing the two prices side by side, with the PuraClear price in green (connoting value) and the DermaTrūe price in red (connoting expense). The in-store POS displays use a similar visual format, prominently featuring the two price points in large typeface on shelf-talker cards and counter displays placed in close proximity to DermaTrūe products.
B. Investigation Findings — The apples-to-Oranges Comparison
Our investigation has determined that the price comparison is fundamentally misleading because it compares two products that are neither comparable in size, composition, nor intended use.
The PuraClear product cited in the comparison is the PuraClear Spot Treatment, a single 1.0 oz. tube retailing at $12.99. The PuraClear Spot Treatment is a standalone topical spot treatment designed for application to individual blemishes.
The DermaTrūe product cited in the comparison is the DermaTrūe Complete Acne System, a three-piece acne-care regimen kit containing:
• A 2.0 oz. cleanser
• A 1.5 oz. treatment gel
• A 1.7 oz. moisturizer
The DermaTrūe Complete Acne System contains a total of 5.2 oz. of product across three distinct formulations and retails at $28.99.
Per-ounce price analysis. The true per-ounce pricing reveals that the campaign's "half the price" claim inverts the actual price relationship:
The per-ounce price of PuraClear ($12.99/oz.) is more than 2.3 times the per-ounce price of DermaTrūe ($5.57/oz.). Far from being available at "half the price," PuraClear is in fact significantly more expensive per unit of product than DermaTrūe when measured on any reasonable volumetric basis.
The use of "comparable" is false. The advertisement's characterization of the PuraClear Spot Treatment and the DermaTrūe Complete Acne System as "comparable" products is itself false. A single 1.0 oz. spot-treatment tube is not comparable to a three-piece, 5.2 oz. acne-care system kit containing a cleanser, treatment gel, and moisturizer. The two products differ in quantity (by a factor of 5.2), in composition (one product versus three), and in function (targeted spot treatment versus comprehensive acne-care regimen). The word "comparable" falsely implies equivalence and invites the consumer to treat the dollar-price comparison as an apples-to-apples comparison when it is, in reality, a fundamentally misleading apples-to-oranges comparison.
C. Legal Analysis — Implicitly False / Misleading
The price-comparison claim presents a nuanced legal question that may be characterized either as literally false or as implicitly false and misleading, depending on which aspect of the claim a court focuses upon.
Literally false elements. The use of the word "comparable" to describe a 1.0 oz. tube and a 5.2 oz. three-piece kit is, in our assessment, literally false. The two products are not comparable in any meaningful sense — they differ in volume by a factor of more than five, they differ in the number of distinct products included, and they differ in the scope of their intended use. If a court agrees that the "comparable" characterization is literally false, no extrinsic evidence of consumer deception would be required.
Implicitly misleading elements. Even if a court were to focus on the raw dollar figures cited in the advertisement ($12.99 versus $28.99) — which are themselves technically accurate — the overall net impression of the advertisement is that PuraClear is the less expensive product. The advertisement's use of the phrase "half the price," combined with the visual formatting (green for PuraClear, red for DermaTrūe) and the word "comparable," creates a clear and unambiguous net impression that PuraClear offers a price advantage over DermaTrūe. That impression is false. Under the Lanham Act, a claim that is literally true in isolation but misleading in context is actionable where extrinsic evidence — such as a consumer-perception survey — demonstrates that a significant portion of consumers were actually deceived. See Time Warner Cable, Inc. v. DIRECTV, Inc., 497 F.3d 144, 153 (2d Cir. 2007); Calderon Corporation v. Smithkline Beecham Corp., 960 F.2d 294, 297-98 (2d Cir. 1992).
Here, the consumer-perception survey evidence developed by Dr. Eleanor Fisk (discussed in Section VI below) strongly supports a finding that consumers were actually deceived about the relative pricing of PuraClear and DermaTrūe products as a result of the campaign.
Under New York GBL §§ 349 and 350, the standard is whether the advertisement is likely to mislead a reasonable consumer acting reasonably under the circumstances. See Stutman v. Chem. Bank, 95 N.Y.2d 24, 29 (2000). The price comparison — with its misleading "comparable" characterization, its omission of per-unit pricing, and its visual formatting designed to accentuate a false price differential — is likely to mislead a reasonable consumer.
NAD preliminary recommendation. The NAD's August 15, 2025 preliminary recommendation that Apex discontinue or modify the price-comparison claim provides persuasive, though non-binding, corroborating authority. While NAD recommendations do not carry the force of law, courts have acknowledged that NAD findings may be considered as probative evidence in Lanham Act cases. See, e.g., Clorox Co. v. Greaves Group, 228 F.3d 24, 36-37 (1st Cir. 2000).
Strength of claim: Strong. The mathematical disparity between the per-ounce prices is dramatic and easily demonstrable. The use of "comparable" to equate a 1.0 oz. tube with a 5.2 oz. three-piece kit is indefensible. The survey evidence provides a strong factual foundation for the implicitly-misleading theory. The NAD's preliminary recommendation provides additional support.
D. Evidentiary Gaps and Further Investigation Needed
1. Internal communications regarding product selection. We need to obtain internal Apex and Brightline Creative Partners communications regarding the selection of the PuraClear Spot Treatment and the DermaTrūe Complete Acne System as the two comparator products for the price claim. Any evidence that Apex or Brightline deliberately selected the smallest PuraClear product and the largest (by dollar price) DermaTrūe product to maximize the apparent price differential — while knowing the per-ounce comparison told a different story — would be powerful evidence of willful deception.
2. Awareness of per-ounce pricing. Any internal discussion of per-ounce or per-unit pricing, or any recognition that the comparison was misleading on a volumetric basis, would be directly relevant to willfulness and to rebutting an anticipated defense that the stated prices are literally accurate.
3. Sales data on consumer behavior. Data showing shifts in consumer purchasing behavior — particularly consumers switching from DermaTrūe to PuraClear — based on perceived price advantage would corroborate the deceptive effect of the price claim and support both the damages and irreparable-harm analyses.
4. Additional survey data. Dr. Eleanor Fisk may be engaged to design a supplemental survey specifically isolating the price-comparison claim to measure the extent to which consumers believed PuraClear was less expensive on a per-unit basis, and whether consumers understood the products being compared were not equivalent in size or composition.
V. Analysis of Claim Category 3: The False "Clean" Ingredients Claim
A. The Claim as Made
The campaign's "clean" ingredients claim is presented in substantially the following verbatim form across all campaign media channels — television, digital video, in-store POS displays, print, and the campaign landing page:
"Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances."
The operative word in this claim is "Unlike." By stating "Unlike DermaTrūe," the advertisement necessarily asserts — and a reasonable consumer would necessarily understand — that DermaTrūe products do contain parabens, sulfates, and/or synthetic fragrances. The entire force of the claim depends on the implicit assertion that DermaTrūe lacks the "clean" ingredient profile that PuraClear possesses.
B. Investigation Findings — DermaTrūe Pure Reformulation
Our investigation has established that the "clean" ingredients claim is demonstrably false.
In 2024 — well before the launch of Apex's campaign on June 2, 2025 — Meridian completed a comprehensive reformulation of its DermaTrūe product line under the sub-brand "DermaTrūe Pure." The reformulation was undertaken in response to growing consumer demand for personal-care products formulated without parabens, sulfates, and synthetic fragrances. The DermaTrūe Pure reformulation was accompanied by updated product packaging (which prominently identifies the products as "paraben-free, sulfate-free, and fragrance-free"), updated product information on Meridian's corporate website and e-commerce platforms, and a trade-press and consumer-press marketing campaign announcing the reformulation.
The reformulated DermaTrūe Pure product line is, in fact, free of parabens, sulfates, and synthetic fragrances. This has been independently confirmed by laboratory testing.
Beacon Scientific Laboratories LLC (44 Industrial Parkway, Edison, New Jersey 08817), an independent analytical testing laboratory, issued Lab Report No. BSL-2025-0412 on March 15, 2025 — nearly three months before Apex launched the PuraClear Truth campaign. The Beacon Scientific report documents a comprehensive ingredient analysis of the full DermaTrūe Pure product line using high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and other standard analytical methodologies. The report's conclusions are unequivocal:
• No parabens (including methylparaben, ethylparaben, propylparaben, butylparaben, and isopropylparaben) were detected in any DermaTrūe Pure product tested.
• No sulfates (including sodium lauryl sulfate and sodium laureth sulfate) were detected in any DermaTrūe Pure product tested.
• No synthetic fragrances were detected in any DermaTrūe Pure product tested.
The Beacon Scientific lab report directly and definitively contradicts Apex's claim that DermaTrūe products contain parabens, sulfates, or synthetic fragrances. The claim was false at the time the campaign launched and remains false today.
C. Legal Analysis — Literally False
The claim that DermaTrūe contains parabens, sulfates, and/or synthetic fragrances — which is the necessary and unavoidable implication of stating that "Unlike DermaTrūe, PuraClear is 100% free" of these substances — is literally false. The Beacon Scientific lab report provides objective, third-party scientific evidence that the DermaTrūe Pure line does not contain any of the ingredients identified in the Apex advertisement.
As a literally false claim, no consumer survey or other extrinsic evidence of deception is required under the Lanham Act. See Calderon Corporation Eprova AG v. Gnosis S.p.A., 760 F.3d 247, 255 (2d Cir. 2014). The Beacon Scientific lab report alone is sufficient to establish the falsity of the claim.
The claim is also actionable under New York GBL §§ 349 and 350 as a deceptive and misleading statement about a competitor's product that is likely to mislead a reasonable consumer.
Strength of claim: Strong. The Beacon Scientific lab report provides clear, objective, third-party scientific evidence definitively refuting Apex's ingredients claim. This is a straightforward literal-falsity case with no reasonable ambiguity.
Willfulness indicator. Apex had a duty to verify claims about a competitor's product before disseminating them in a nationwide advertising campaign. The DermaTrūe Pure reformulation was publicly marketed, prominently featured on product packaging and Meridian's website, and covered in trade press. The updated packaging — which clearly states "paraben-free, sulfate-free, and fragrance-free" — was available on retail shelves at the same drugstore chains where Apex sells PuraClear products. Apex's failure to verify the accuracy of its "clean" ingredients claim before launching the campaign — or, alternatively, its awareness of the reformulation and its decision to proceed with the false claim regardless — indicates, at minimum, reckless disregard for the truth. Reckless disregard is sufficient to establish willfulness for purposes of enhanced damages and attorneys' fees under the Lanham Act. See George Basch Co. v. Blue Coral, Inc., 968 F.2d 1532, 1540 (2d Cir. 1992).
D. Evidentiary Gaps and Further Investigation Needed
1. Apex pre-launch ingredient testing or review. We need to determine whether Apex or Brightline Creative Partners conducted any ingredient testing, formulation review, or other verification of DermaTrūe's current product composition before launching the campaign. The absence of any such testing or review would support the willfulness analysis; the existence of testing that confirmed the reformulation but was ignored would be even more damaging.
2. Awareness of the DermaTrūe Pure reformulation. We should seek evidence — including competitive intelligence reports, market research, trade-press monitoring, product samples purchased for analysis, retail shelf observations, or any other internal Apex documentation — establishing that Apex was aware of the DermaTrūe Pure reformulation prior to June 2, 2025. Given that the reformulation was publicly marketed and the reformulated products were sold at the same retail chains where PuraClear is sold, it would be difficult for Apex to credibly deny awareness.
3. Internal communications on the "clean" claim. Communications among Apex personnel (particularly Dr. Guerrero, Rachel Emory, and Marcus Devlin) and Brightline Creative Partners regarding the formulation, vetting, and approval of the "clean" ingredients claim are critical to establishing the knowledge and intent elements of the willfulness analysis.
4. Chain-of-custody and testing protocols for the Beacon Scientific report. To ensure the admissibility of Lab Report No. BSL-2025-0412 at trial and in support of the preliminary injunction motion, we should confirm the chain-of-custody for the product samples tested, verify that testing was conducted in accordance with Good Laboratory Practice (GLP) standards, and obtain a declaration from the responsible Beacon Scientific analyst authenticating the report.
VI. Consumer-Perception Survey Evidence
Dr. Eleanor Fisk of Fisk Analytics Group LLC (101 Federal Street, Suite 2600, Boston, Massachusetts 02110) conducted a post-campaign consumer-perception survey on behalf of Meridian. Dr. Fisk is a recognized expert in survey methodology and consumer perception analysis, with extensive experience designing and conducting surveys for use in false-advertising and trademark litigation. Her engagement rate is $850 per hour.
Methodology. The survey was fielded on August 22, 2025, and employed a nationally representative sample of 1,500 adult respondents aged 18 and older. The sample was stratified to ensure demographic representativeness across age, gender, race/ethnicity, household income, and geographic region. The margin of error for the overall sample is ±2.5% at the 95% confidence level. Respondents were screened for familiarity with acne-treatment products and were asked a series of closed-ended and open-ended questions regarding their perceptions of PuraClear and DermaTrūe products, including questions designed to assess whether respondents had been exposed to "The PuraClear Truth" campaign and, if so, what impressions the campaign conveyed.
The survey results were compared against a baseline survey conducted in January 2025 — five months prior to the launch of the Apex campaign — using the same screening criteria and sampling methodology.
Key Findings:
• Perceived overpricing of DermaTrūe. Among respondents who recalled exposure to the PuraClear advertisements, 34% believed that DermaTrūe products were "overpriced" — up from only 11% in the January 2025 baseline survey. This represents a 23-percentage-point increase in the perception that DermaTrūe is overpriced, directly attributable to the campaign's price-comparison messaging.
• Perceived inferior efficacy of DermaTrūe. Among respondents who recalled exposure to the PuraClear advertisements, 27% believed that DermaTrūe was "less effective than PuraClear" — up from only 8% in the January 2025 baseline survey. This represents a 19-percentage-point increase in the perception that DermaTrūe is less effective, directly attributable to the campaign's clinical superiority claim.
Significance of the survey results. These results demonstrate actual consumer confusion and deception attributable to "The PuraClear Truth" campaign. The magnitude of the shifts — 23 and 19 percentage points, respectively — far exceeds the survey's margin of error and cannot reasonably be attributed to factors other than the campaign.
For purposes of the legal analysis, the survey evidence serves multiple functions:
• For Claims 1 (clinical superiority) and 3 (clean ingredients), the literally-false arguments obviate the need for survey evidence to establish deception. However, the survey evidence strengthens these claims by demonstrating that the false statements actually deceived consumers and materially influenced their perceptions and, presumably, their purchasing decisions. This is particularly relevant to the damages analysis and to the showing of irreparable harm for preliminary injunction purposes.
• For Claim 2 (price comparison), where the claim may be characterized as implicitly misleading rather than literally false, the survey evidence is critical to establishing that consumers were actually deceived. The 23-percentage-point increase in the perception that DermaTrūe is "overpriced" strongly supports a finding of actual deception under the Lanham Act and under NY GBL §§ 349 and 350.
• Across all claims, the survey evidence supports the irreparable-harm showing for the preliminary injunction motion by establishing that the campaign has caused measurable, ongoing erosion of consumer perceptions of the DermaTrūe brand that may persist well beyond the cessation of the campaign itself.
Additional survey work. If Apex contests causation — i.e., argues that the shifts in consumer perception are attributable to factors other than the campaign — Dr. Fisk may need to design a follow-up survey employing a control-group methodology that isolates each claim category individually. This additional survey work should be discussed as part of the expert discovery plan and budgeted accordingly.
VII. Impact on Meridian — Damages Overview
A. Lost Revenue and Profits
The financial impact of Apex's campaign on Meridian's DermaTrūe product line is substantial and accelerating. A comparison of DermaTrūe quarterly revenue data reveals the following:
• DermaTrūe Q3 2025 revenue (July – September 2025, estimated): $29.4 million
• DermaTrūe Q3 2024 revenue: $36.8 million
• Quarter-over-quarter decline: $7.4 million (20.1%)
This $7.4 million decline in quarterly revenue occurred during a period in which the broader acne-treatment market was stable, Meridian's other product lines (Velara and SkinSense) performed in line with expectations, and no significant competitive entries other than Apex's campaign were introduced into the market. The timing and magnitude of the decline are consistent with the launch and sustained dissemination of the Apex campaign.
Applying Meridian's DermaTrūe gross margin of 62.5%, the estimated lost gross profit attributable to the campaign for Q3 2025 alone is:
$7.4 million × 62.5% = $4.625 million
If the campaign continues unchecked and the current rate of decline persists, annualized lost gross profits are estimated at:
$4.625 million × 4 = $18.5 million
This estimate is conservative. It assumes the rate of decline does not accelerate, which may not be realistic given the compounding effects of the Kingsley shelf-space reduction (discussed below) and the ongoing erosion of consumer confidence in the DermaTrūe brand.
B. Retailer Impact — Kingsley Drug Stores
On August 5, 2025, Kingsley Drug Stores LLC — a major national retail drugstore chain with over 2,400 stores across 38 states — notified Meridian that it would reduce DermaTrūe shelf space by 30% effective October 1, 2025. The notification cited "declining consumer demand" as the basis for the reduction.
The Kingsley notification is directly attributable to the Apex campaign. DermaTrūe had maintained stable or growing shelf space at Kingsley locations for the preceding five years. The timing of the shelf-space reduction — coming just two months after the campaign launch and in the immediate wake of the campaign's in-store POS displays, some of which were placed in Kingsley stores — confirms the causal link between the campaign and the reduction.
Meridian estimates the annual revenue impact of the Kingsley shelf-space reduction at approximately $4.1 million. This figure is based on historical per-store DermaTrūe sales data at Kingsley locations, adjusted for the 30% reduction in shelf space and the associated loss of consumer visibility and impulse-purchase opportunities.
The Kingsley notification also provides the factual predicate for a tortious interference with business relations claim against Apex, as discussed in Section VIII.E below.
C. Brand-Perception Damage
The Fisk Analytics survey data discussed in Section VI demonstrates significant, measurable erosion of consumer trust in and perception of the DermaTrūe brand. The 23-percentage-point increase in the perception that DermaTrūe is "overpriced" and the 19-percentage-point increase in the perception that DermaTrūe is "less effective" represent substantial damage to a brand that Meridian has spent years and millions of dollars building and maintaining.
Brand-perception damage of this nature may persist well beyond the cessation of the offending campaign. Consumer attitudes, once shifted, are not easily reversed, and the corrective effect of a retraction or injunction is typically incomplete and delayed. Moreover, brand-perception damage may be difficult to quantify with precision in dollar terms, particularly the long-term effects on consumer loyalty, repeat-purchase rates, and willingness to recommend DermaTrūe to others. This difficulty of quantification is itself a basis for a finding of irreparable harm supporting injunctive relief. See Salinger v. Colting, 607 F.3d 68, 81 (2d Cir. 2010) (recognizing that harms difficult to quantify in monetary terms may constitute irreparable harm).
D. Apex's Unjust Enrichment / Disgorgement
Under the Lanham Act, a prevailing plaintiff may recover the defendant's profits attributable to the false advertising. 15 U.S.C. § 1117(a). Disgorgement of the defendant's profits serves the dual purposes of compensating the plaintiff for diverted sales and deterring the defendant from future false advertising.
Based on available data, we estimate Apex's incremental PuraClear revenue attributable to the campaign during Q2 and Q3 2025 at approximately $19.8 million. This figure represents the increase in PuraClear sales above the pre-campaign trendline, adjusted for seasonal factors and overall market growth.
Applying Apex's estimated PuraClear gross margin of 56.5%, the estimated disgorgement amount is:
$19.8 million × 56.5% = $11.2 million
We have identified Dr. Raymond Choe of Marlowe Asset Management Economic Consulting LLC (1750 K Street NW, Suite 800, Washington, DC 20006) as a damages expert qualified to prepare a comprehensive lost-profits and disgorgement analysis. Dr. Choe has extensive experience in damages modeling in false-advertising and unfair-competition cases and has been qualified as an expert in multiple federal courts. His engagement rate is $925 per hour.
VIII. Legal Framework and Viability of Claims
A. Lanham Act § 43(a), 15 U.S.C. § 1125(a) — False Advertising
Section 43(a) of the Lanham Act prohibits the use of "any false or misleading description of fact, or false or misleading representation of fact, which . . . in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographic origin of his or her or another person's goods, services, or commercial activities." 15 U.S.C. § 1125(a)(1)(B).
To prevail on a false advertising claim under the Lanham Act, a plaintiff must establish:
(1) The defendant made a false or misleading statement of fact in commercial advertising or promotion;
(2) The statement actually deceived or has the tendency to deceive a substantial segment of the target audience;
(3) The deception is material — i.e., it is likely to influence the purchasing decisions of the consuming public;
(4) The advertised goods traveled in interstate commerce; and
(5) The plaintiff has been or is likely to be injured as a result of the false advertising.
See McNeil-PPC, Inc. v. Northpoint Holdings, 351 F. Supp. 2d 226, 247 (S.D.N.Y. 2005); Church & Dwight Co. v. SPD Swiss Precision Diagnostics, GmBH, 843 F.3d 48, 65 (2d Cir. 2016).
All three claim categories satisfy these elements. With respect to element (1), each claim category involves a specific, verifiable factual assertion in a nationwide advertising campaign that plainly constitutes "commercial advertising or promotion." With respect to element (2), Claims 1 (clinical superiority) and 3 (clean ingredients) are literally false, which under Second Circuit precedent eliminates the need to prove actual consumer deception. Claim 2 (price comparison) is, at minimum, implicitly misleading, and the Fisk Analytics survey evidence demonstrates actual consumer deception. With respect to element (3), claims about clinical efficacy, price, and ingredient safety are inherently material to consumer purchasing decisions for acne-treatment products. With respect to element (4), the campaign is disseminated nationwide across multiple media channels, and both PuraClear and DermaTrūe products are sold in interstate commerce. With respect to element (5), Meridian has documented a $7.4 million Q3 revenue decline, a pending $4.1 million annual impact from the Kingsley shelf-space reduction, and significant brand-perception damage.
Available relief. The Lanham Act provides for injunctive relief, compensatory damages (including lost profits), disgorgement of the defendant's profits, an award for corrective advertising costs, and reasonable attorneys' fees in "exceptional cases." 15 U.S.C. §§ 1116, 1117(a). In addition, the court has discretion to treble the damages award under 15 U.S.C. § 1117(a) if the defendant's conduct is found to be willful. Based on the annualized lost-profit estimate of $18.5 million, potential treble damages could reach up to $55.5 million. Given the evidence of willfulness — particularly the fabricated study citation and the failure to verify the "clean" ingredients claim despite readily available public information — treble damages and an "exceptional case" finding for attorneys' fees are realistic possibilities.
B. New York General Business Law § 349 — Deceptive Acts and Practices
New York GBL § 349 prohibits "[d]eceptive acts or practices in the conduct of any business, trade or commerce or in the furnishing of any service in this state." To establish a claim under § 349, a plaintiff must show:
(1) The conduct is consumer-oriented;
(2) The act or practice is materially misleading; and
(3) The plaintiff has been injured as a result of the deceptive act or practice.
See Stutman v. Chem. Bank, 95 N.Y.2d 24, 29 (2000); Oswego Laborers' Local 214 Pension Fund v. Marine Midland Bank, N.A., 85 N.Y.2d 20, 25 (1995).
The nationwide consumer advertising campaign is plainly consumer-oriented — it is directed to, and intended to influence the purchasing decisions of, individual consumers of acne-treatment products. The false claims identified in all three categories are materially misleading under any reasonable standard. And Meridian has been injured through lost sales, brand-perception damage, and retailer relationships. Section 349 further provides for statutory damages, treble damages (up to $1,000), and reasonable attorneys' fees. See N.Y. GBL § 349(h). While the individual statutory damages under § 349 are modest, the claim provides an additional basis for relief and may carry particular weight with a jury in establishing the deceptive character of the campaign.
C. New York General Business Law § 350 — False Advertising
New York GBL § 350 provides that "[f]alse advertising in the conduct of any business, trade or commerce or in the furnishing of any service in this state is hereby declared unlawful." To state a claim under § 350, a plaintiff must establish:
(1) The defendant's conduct constitutes an "advertisement";